Molecular Exploitation of Apoptosis Pathways in Prostate Cancer.:
This book focuses on the functional significance of targeting apoptosis for the treatment of prostate cancer. New concepts on the challenges relating to the development of resistance by androgen-independent tumors are introduced, in terms of the contribution of anoikis and cross-talk of androgens wi...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Singapore :
World Scientific,
2012.
|
| Schriftenreihe: | Molecular medicine and medicinal chemistry.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | This book focuses on the functional significance of targeting apoptosis for the treatment of prostate cancer. New concepts on the challenges relating to the development of resistance by androgen-independent tumors are introduced, in terms of the contribution of anoikis and cross-talk of androgens with key growth factor signaling pathways. This volume also provides insightful discussion on the exploitation of the apoptotic and angiogenic synergism towards complete eradication of prostate tumors. Last but not least, it includes reflections on the drug development challenge based on the analysis. |
| Beschreibung: | 9.1 Aspirin and Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). |
| Beschreibung: | 1 online resource (230 pages) |
| ISBN: | 9781848164505 1848164505 |
Internformat
MARC
| LEADER | 00000cam a2200000Mu 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-ocn794328399 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr |n|---||||| | ||
| 008 | 120528s2012 si o 000 0 eng d | ||
| 040 | |a EBLCP |b eng |e pn |c EBLCP |d OCLCQ |d N$T |d YDXCP |d OCLCQ |d OCLCA |d OCLCF |d OCLCO |d OCLCQ |d OCLCO |d DEBSZ |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO |d AGLDB |d ZCU |d MERUC |d OCLCQ |d STF |d VTS |d ICG |d TOF |d OCLCQ |d DKC |d OCLCQ |d AJS |d OCLCO |d LUU |d OCLCQ |d OCLCO |d OCLCL | ||
| 019 | |a 1264787893 |a 1264793174 | ||
| 020 | |a 9781848164505 |q (electronic bk.) | ||
| 020 | |a 1848164505 |q (electronic bk.) | ||
| 035 | |a (OCoLC)794328399 |z (OCoLC)1264787893 |z (OCoLC)1264793174 | ||
| 050 | 4 | |a RC280.P7 | |
| 060 | 0 | 0 | |a 2012 E-221 |
| 060 | 1 | 0 | |a WJ 762 |
| 072 | 7 | |a HEA |x 039030 |2 bisacsh | |
| 072 | 7 | |a MED |x 062000 |2 bisacsh | |
| 082 | 7 | |a 616.99463 | |
| 049 | |a MAIN | ||
| 100 | 1 | |a Kyprianou, Natasha. | |
| 245 | 1 | 0 | |a Molecular Exploitation of Apoptosis Pathways in Prostate Cancer. |
| 260 | |a Singapore : |b World Scientific, |c 2012. | ||
| 300 | |a 1 online resource (230 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Molecular Medicine and Medicinal Chemistry | |
| 505 | 0 | |a Preface; Contents; Chapter 1 Introduction: Prostate Cancer; Chapter 2 The Prostate Gland Dynamics; Chapter 3 Apoptosis Pathways Signaling Execution of Cancer Cells; 3.1 Cell Choices of Life and Death; 3.1.1 "Classic" apoptosis; 3.1.2 Anoikis; 3.2 Caspases: The Apoptosis Executioners in a Therapeutic Setting; 3.3 The Mitochondrion: A Convenient Cell-Killing Platform; 3.4 Cell Surface Death Receptors and the FAS Ligand; 3.5 Meet the BCL-2 Family: Governors of Cell Survival and Death; 3.6 The Transcriptional Controllers; 3.7 The p53 Tumor Suppressor. | |
| 505 | 8 | |a 3.8 PTEN/PI3K/AKT: The Downstream Intracellular Players3.9 The Antagonists of Death: Inhibitors of Apoptosis Proteins (IAPs); 3.10 Apoptosis Signaling in the Endoplasmic Reticulum: A Death Platform for Stress; 3.11 The Tumor Microenvironment: Extracellular Forces Control Intracellular Death Outcomes; 3.11.1 Role of hypoxia; 3.11.2 The key growth factors; 3.11.3 Inflammation; Chapter 4 Androgen Receptor-Mediated Apoptosis: Significance in Development of Castration-Resistant Prostate Cancer; 4.1 The Androgen Receptor (AR); 4.2 Androgen Ablation: The Glory and the Failures. | |
| 505 | 8 | |a 4.3 AR Status in Castration-Resistant Prostate Cancer4.4 AR Interactions with Growth Factor Signaling Leads to Apoptosis; 4.4.1 AR connects with EGF; 4.4.2 AR and IGF interactions; 4.4.3 AR and TGF-ß: partners in life and death (of the cell); 4.4.4 AR and FGF interactions; 4.4.5 AR and VEGF: Vascular exchanges for the "road"; 4.4.6 AR and growth factor interplay in the stroma; Chapter 5 Anoikis in Prostate Cancer Metastasis; 5.1 Anoikis Interrupted: Survival of the Homeless (Cells); 5.2 The Integrin Connection; 5.3 Impairing the Route to Angiogenesis; 5.3.1 Doxazosin; 5.3.2 Suramin. | |
| 505 | 8 | |a 5.3.3 Thalidomide5.3.4 Bevacizumab; 5.3.5 SU5416; 5.4 Anoikis and the Tumor Microenvironment: No "Resting" in the Stroma; 5.5 Signaling the "Homeless" State: Intracellular Anoikis Effectors; 5.6 Significance of Apoptosis in Cytoskeleton and Microtubule Targeting; 5.7 Autophagy: The Cellular Benefits of Starving to Death; Chapter 6 Epithelial-Mesenchymal Transition (EMT) in Prostate Cancer Metastasis; Chapter 7 Novel Molecular Therapeutics for Targeting Castration-Resistant Prostate Cancer; 7.1 Therapeutic Targeting of TGF-ß Signaling. | |
| 505 | 8 | |a 7.2 Exploitation of Quinazolines: Lifting Anoikis Resistance to Impair Metastasis7.3 Receptor Tyrosine Kinase Targeting; 7.4 Histone Deacetylase Inhibitors (HDACs): Therapeutic Inhibitors; 7.5 Selective Death Action by Cancer-Specific PAR-4 in Prostate Tumors; 7.6 Death Synergy Between Proteosome and Death Receptor Leads to Tumor Regression; 7.7 The SERCA Pump as a Therapeutic Target; 7.8 Endothelin-Receptor Antagonists; 7.9 The Power of Sex Steroid Targeting; Chapter 8 Apoptotic-Based Molecular Markers of Therapeutic Response; Chapter 9 Role of Apoptosis in Prostate Cancer Prevention. | |
| 500 | |a 9.1 Aspirin and Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). | ||
| 520 | |a This book focuses on the functional significance of targeting apoptosis for the treatment of prostate cancer. New concepts on the challenges relating to the development of resistance by androgen-independent tumors are introduced, in terms of the contribution of anoikis and cross-talk of androgens with key growth factor signaling pathways. This volume also provides insightful discussion on the exploitation of the apoptotic and angiogenic synergism towards complete eradication of prostate tumors. Last but not least, it includes reflections on the drug development challenge based on the analysis. | ||
| 588 | 0 | |a Print version record. | |
| 650 | 0 | |a Prostate |x Cancer |x Treatment. | |
| 650 | 0 | |a Apoptosis. |0 http://id.loc.gov/authorities/subjects/sh91000743 | |
| 650 | 2 | |a Apoptosis |0 https://id.nlm.nih.gov/mesh/D017209 | |
| 650 | 6 | |a Prostate |x Cancer |x Traitement. | |
| 650 | 6 | |a Apoptose. | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x Cancer. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Oncology. |2 bisacsh | |
| 650 | 7 | |a Apoptosis |2 fast | |
| 650 | 7 | |a Prostate |x Cancer |x Treatment |2 fast | |
| 758 | |i has work: |a Molecular exploitation of apoptosis pathways in prostate cancer (Text) |1 https://id.oclc.org/worldcat/entity/E39PCFPBpRgGyTjmhkxtHdxVqP |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |a Kyprianou, Natasha. |t Molecular Exploitation of Apoptosis Pathways in Prostate Cancer. |d Singapore : World Scientific, ©2012 |z 9781848164499 |
| 830 | 0 | |a Molecular medicine and medicinal chemistry. |0 http://id.loc.gov/authorities/names/n2011180846 | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=457203 |3 Volltext |
| 938 | |a EBL - Ebook Library |b EBLB |n EBL919104 | ||
| 938 | |a EBSCOhost |b EBSC |n 457203 | ||
| 938 | |a YBP Library Services |b YANK |n 7652859 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-ocn794328399 |
|---|---|
| _version_ | 1816881795716612096 |
| adam_text | |
| any_adam_object | |
| author | Kyprianou, Natasha |
| author_facet | Kyprianou, Natasha |
| author_role | |
| author_sort | Kyprianou, Natasha |
| author_variant | n k nk |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RC280 |
| callnumber-raw | RC280.P7 |
| callnumber-search | RC280.P7 |
| callnumber-sort | RC 3280 P7 |
| callnumber-subject | RC - Internal Medicine |
| collection | ZDB-4-EBA |
| contents | Preface; Contents; Chapter 1 Introduction: Prostate Cancer; Chapter 2 The Prostate Gland Dynamics; Chapter 3 Apoptosis Pathways Signaling Execution of Cancer Cells; 3.1 Cell Choices of Life and Death; 3.1.1 "Classic" apoptosis; 3.1.2 Anoikis; 3.2 Caspases: The Apoptosis Executioners in a Therapeutic Setting; 3.3 The Mitochondrion: A Convenient Cell-Killing Platform; 3.4 Cell Surface Death Receptors and the FAS Ligand; 3.5 Meet the BCL-2 Family: Governors of Cell Survival and Death; 3.6 The Transcriptional Controllers; 3.7 The p53 Tumor Suppressor. 3.8 PTEN/PI3K/AKT: The Downstream Intracellular Players3.9 The Antagonists of Death: Inhibitors of Apoptosis Proteins (IAPs); 3.10 Apoptosis Signaling in the Endoplasmic Reticulum: A Death Platform for Stress; 3.11 The Tumor Microenvironment: Extracellular Forces Control Intracellular Death Outcomes; 3.11.1 Role of hypoxia; 3.11.2 The key growth factors; 3.11.3 Inflammation; Chapter 4 Androgen Receptor-Mediated Apoptosis: Significance in Development of Castration-Resistant Prostate Cancer; 4.1 The Androgen Receptor (AR); 4.2 Androgen Ablation: The Glory and the Failures. 4.3 AR Status in Castration-Resistant Prostate Cancer4.4 AR Interactions with Growth Factor Signaling Leads to Apoptosis; 4.4.1 AR connects with EGF; 4.4.2 AR and IGF interactions; 4.4.3 AR and TGF-ß: partners in life and death (of the cell); 4.4.4 AR and FGF interactions; 4.4.5 AR and VEGF: Vascular exchanges for the "road"; 4.4.6 AR and growth factor interplay in the stroma; Chapter 5 Anoikis in Prostate Cancer Metastasis; 5.1 Anoikis Interrupted: Survival of the Homeless (Cells); 5.2 The Integrin Connection; 5.3 Impairing the Route to Angiogenesis; 5.3.1 Doxazosin; 5.3.2 Suramin. 5.3.3 Thalidomide5.3.4 Bevacizumab; 5.3.5 SU5416; 5.4 Anoikis and the Tumor Microenvironment: No "Resting" in the Stroma; 5.5 Signaling the "Homeless" State: Intracellular Anoikis Effectors; 5.6 Significance of Apoptosis in Cytoskeleton and Microtubule Targeting; 5.7 Autophagy: The Cellular Benefits of Starving to Death; Chapter 6 Epithelial-Mesenchymal Transition (EMT) in Prostate Cancer Metastasis; Chapter 7 Novel Molecular Therapeutics for Targeting Castration-Resistant Prostate Cancer; 7.1 Therapeutic Targeting of TGF-ß Signaling. 7.2 Exploitation of Quinazolines: Lifting Anoikis Resistance to Impair Metastasis7.3 Receptor Tyrosine Kinase Targeting; 7.4 Histone Deacetylase Inhibitors (HDACs): Therapeutic Inhibitors; 7.5 Selective Death Action by Cancer-Specific PAR-4 in Prostate Tumors; 7.6 Death Synergy Between Proteosome and Death Receptor Leads to Tumor Regression; 7.7 The SERCA Pump as a Therapeutic Target; 7.8 Endothelin-Receptor Antagonists; 7.9 The Power of Sex Steroid Targeting; Chapter 8 Apoptotic-Based Molecular Markers of Therapeutic Response; Chapter 9 Role of Apoptosis in Prostate Cancer Prevention. |
| ctrlnum | (OCoLC)794328399 |
| dewey-full | 616.99463 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99463 |
| dewey-search | 616.99463 |
| dewey-sort | 3616.99463 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>06132cam a2200637Mu 4500</leader><controlfield tag="001">ZDB-4-EBA-ocn794328399</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |n|---|||||</controlfield><controlfield tag="008">120528s2012 si o 000 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">EBLCP</subfield><subfield code="b">eng</subfield><subfield code="e">pn</subfield><subfield code="c">EBLCP</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">N$T</subfield><subfield code="d">YDXCP</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCA</subfield><subfield code="d">OCLCF</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">DEBSZ</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">AGLDB</subfield><subfield code="d">ZCU</subfield><subfield code="d">MERUC</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">STF</subfield><subfield code="d">VTS</subfield><subfield code="d">ICG</subfield><subfield code="d">TOF</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">DKC</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">AJS</subfield><subfield code="d">OCLCO</subfield><subfield code="d">LUU</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">1264787893</subfield><subfield code="a">1264793174</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781848164505</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1848164505</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)794328399</subfield><subfield code="z">(OCoLC)1264787893</subfield><subfield code="z">(OCoLC)1264793174</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC280.P7</subfield></datafield><datafield tag="060" ind1="0" ind2="0"><subfield code="a">2012 E-221</subfield></datafield><datafield tag="060" ind1="1" ind2="0"><subfield code="a">WJ 762</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">HEA</subfield><subfield code="x">039030</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">062000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">616.99463</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kyprianou, Natasha.</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Molecular Exploitation of Apoptosis Pathways in Prostate Cancer.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Singapore :</subfield><subfield code="b">World Scientific,</subfield><subfield code="c">2012.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (230 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Molecular Medicine and Medicinal Chemistry</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Preface; Contents; Chapter 1 Introduction: Prostate Cancer; Chapter 2 The Prostate Gland Dynamics; Chapter 3 Apoptosis Pathways Signaling Execution of Cancer Cells; 3.1 Cell Choices of Life and Death; 3.1.1 "Classic" apoptosis; 3.1.2 Anoikis; 3.2 Caspases: The Apoptosis Executioners in a Therapeutic Setting; 3.3 The Mitochondrion: A Convenient Cell-Killing Platform; 3.4 Cell Surface Death Receptors and the FAS Ligand; 3.5 Meet the BCL-2 Family: Governors of Cell Survival and Death; 3.6 The Transcriptional Controllers; 3.7 The p53 Tumor Suppressor.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">3.8 PTEN/PI3K/AKT: The Downstream Intracellular Players3.9 The Antagonists of Death: Inhibitors of Apoptosis Proteins (IAPs); 3.10 Apoptosis Signaling in the Endoplasmic Reticulum: A Death Platform for Stress; 3.11 The Tumor Microenvironment: Extracellular Forces Control Intracellular Death Outcomes; 3.11.1 Role of hypoxia; 3.11.2 The key growth factors; 3.11.3 Inflammation; Chapter 4 Androgen Receptor-Mediated Apoptosis: Significance in Development of Castration-Resistant Prostate Cancer; 4.1 The Androgen Receptor (AR); 4.2 Androgen Ablation: The Glory and the Failures.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">4.3 AR Status in Castration-Resistant Prostate Cancer4.4 AR Interactions with Growth Factor Signaling Leads to Apoptosis; 4.4.1 AR connects with EGF; 4.4.2 AR and IGF interactions; 4.4.3 AR and TGF-ß: partners in life and death (of the cell); 4.4.4 AR and FGF interactions; 4.4.5 AR and VEGF: Vascular exchanges for the "road"; 4.4.6 AR and growth factor interplay in the stroma; Chapter 5 Anoikis in Prostate Cancer Metastasis; 5.1 Anoikis Interrupted: Survival of the Homeless (Cells); 5.2 The Integrin Connection; 5.3 Impairing the Route to Angiogenesis; 5.3.1 Doxazosin; 5.3.2 Suramin.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">5.3.3 Thalidomide5.3.4 Bevacizumab; 5.3.5 SU5416; 5.4 Anoikis and the Tumor Microenvironment: No "Resting" in the Stroma; 5.5 Signaling the "Homeless" State: Intracellular Anoikis Effectors; 5.6 Significance of Apoptosis in Cytoskeleton and Microtubule Targeting; 5.7 Autophagy: The Cellular Benefits of Starving to Death; Chapter 6 Epithelial-Mesenchymal Transition (EMT) in Prostate Cancer Metastasis; Chapter 7 Novel Molecular Therapeutics for Targeting Castration-Resistant Prostate Cancer; 7.1 Therapeutic Targeting of TGF-ß Signaling.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">7.2 Exploitation of Quinazolines: Lifting Anoikis Resistance to Impair Metastasis7.3 Receptor Tyrosine Kinase Targeting; 7.4 Histone Deacetylase Inhibitors (HDACs): Therapeutic Inhibitors; 7.5 Selective Death Action by Cancer-Specific PAR-4 in Prostate Tumors; 7.6 Death Synergy Between Proteosome and Death Receptor Leads to Tumor Regression; 7.7 The SERCA Pump as a Therapeutic Target; 7.8 Endothelin-Receptor Antagonists; 7.9 The Power of Sex Steroid Targeting; Chapter 8 Apoptotic-Based Molecular Markers of Therapeutic Response; Chapter 9 Role of Apoptosis in Prostate Cancer Prevention.</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">9.1 Aspirin and Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This book focuses on the functional significance of targeting apoptosis for the treatment of prostate cancer. New concepts on the challenges relating to the development of resistance by androgen-independent tumors are introduced, in terms of the contribution of anoikis and cross-talk of androgens with key growth factor signaling pathways. This volume also provides insightful discussion on the exploitation of the apoptotic and angiogenic synergism towards complete eradication of prostate tumors. Last but not least, it includes reflections on the drug development challenge based on the analysis.</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Print version record.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Prostate</subfield><subfield code="x">Cancer</subfield><subfield code="x">Treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Apoptosis.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh91000743</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Apoptosis</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D017209</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Prostate</subfield><subfield code="x">Cancer</subfield><subfield code="x">Traitement.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Apoptose.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEALTH & FITNESS</subfield><subfield code="x">Diseases</subfield><subfield code="x">Cancer.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Oncology.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Apoptosis</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prostate</subfield><subfield code="x">Cancer</subfield><subfield code="x">Treatment</subfield><subfield code="2">fast</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">Molecular exploitation of apoptosis pathways in prostate cancer (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCFPBpRgGyTjmhkxtHdxVqP</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Kyprianou, Natasha.</subfield><subfield code="t">Molecular Exploitation of Apoptosis Pathways in Prostate Cancer.</subfield><subfield code="d">Singapore : World Scientific, ©2012</subfield><subfield code="z">9781848164499</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Molecular medicine and medicinal chemistry.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2011180846</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=457203</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBL - Ebook Library</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL919104</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">457203</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">7652859</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-ocn794328399 |
| illustrated | Not Illustrated |
| indexdate | 2024-11-27T13:18:24Z |
| institution | BVB |
| isbn | 9781848164505 1848164505 |
| language | English |
| oclc_num | 794328399 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource (230 pages) |
| psigel | ZDB-4-EBA |
| publishDate | 2012 |
| publishDateSearch | 2012 |
| publishDateSort | 2012 |
| publisher | World Scientific, |
| record_format | marc |
| series | Molecular medicine and medicinal chemistry. |
| series2 | Molecular Medicine and Medicinal Chemistry |
| spelling | Kyprianou, Natasha. Molecular Exploitation of Apoptosis Pathways in Prostate Cancer. Singapore : World Scientific, 2012. 1 online resource (230 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Molecular Medicine and Medicinal Chemistry Preface; Contents; Chapter 1 Introduction: Prostate Cancer; Chapter 2 The Prostate Gland Dynamics; Chapter 3 Apoptosis Pathways Signaling Execution of Cancer Cells; 3.1 Cell Choices of Life and Death; 3.1.1 "Classic" apoptosis; 3.1.2 Anoikis; 3.2 Caspases: The Apoptosis Executioners in a Therapeutic Setting; 3.3 The Mitochondrion: A Convenient Cell-Killing Platform; 3.4 Cell Surface Death Receptors and the FAS Ligand; 3.5 Meet the BCL-2 Family: Governors of Cell Survival and Death; 3.6 The Transcriptional Controllers; 3.7 The p53 Tumor Suppressor. 3.8 PTEN/PI3K/AKT: The Downstream Intracellular Players3.9 The Antagonists of Death: Inhibitors of Apoptosis Proteins (IAPs); 3.10 Apoptosis Signaling in the Endoplasmic Reticulum: A Death Platform for Stress; 3.11 The Tumor Microenvironment: Extracellular Forces Control Intracellular Death Outcomes; 3.11.1 Role of hypoxia; 3.11.2 The key growth factors; 3.11.3 Inflammation; Chapter 4 Androgen Receptor-Mediated Apoptosis: Significance in Development of Castration-Resistant Prostate Cancer; 4.1 The Androgen Receptor (AR); 4.2 Androgen Ablation: The Glory and the Failures. 4.3 AR Status in Castration-Resistant Prostate Cancer4.4 AR Interactions with Growth Factor Signaling Leads to Apoptosis; 4.4.1 AR connects with EGF; 4.4.2 AR and IGF interactions; 4.4.3 AR and TGF-ß: partners in life and death (of the cell); 4.4.4 AR and FGF interactions; 4.4.5 AR and VEGF: Vascular exchanges for the "road"; 4.4.6 AR and growth factor interplay in the stroma; Chapter 5 Anoikis in Prostate Cancer Metastasis; 5.1 Anoikis Interrupted: Survival of the Homeless (Cells); 5.2 The Integrin Connection; 5.3 Impairing the Route to Angiogenesis; 5.3.1 Doxazosin; 5.3.2 Suramin. 5.3.3 Thalidomide5.3.4 Bevacizumab; 5.3.5 SU5416; 5.4 Anoikis and the Tumor Microenvironment: No "Resting" in the Stroma; 5.5 Signaling the "Homeless" State: Intracellular Anoikis Effectors; 5.6 Significance of Apoptosis in Cytoskeleton and Microtubule Targeting; 5.7 Autophagy: The Cellular Benefits of Starving to Death; Chapter 6 Epithelial-Mesenchymal Transition (EMT) in Prostate Cancer Metastasis; Chapter 7 Novel Molecular Therapeutics for Targeting Castration-Resistant Prostate Cancer; 7.1 Therapeutic Targeting of TGF-ß Signaling. 7.2 Exploitation of Quinazolines: Lifting Anoikis Resistance to Impair Metastasis7.3 Receptor Tyrosine Kinase Targeting; 7.4 Histone Deacetylase Inhibitors (HDACs): Therapeutic Inhibitors; 7.5 Selective Death Action by Cancer-Specific PAR-4 in Prostate Tumors; 7.6 Death Synergy Between Proteosome and Death Receptor Leads to Tumor Regression; 7.7 The SERCA Pump as a Therapeutic Target; 7.8 Endothelin-Receptor Antagonists; 7.9 The Power of Sex Steroid Targeting; Chapter 8 Apoptotic-Based Molecular Markers of Therapeutic Response; Chapter 9 Role of Apoptosis in Prostate Cancer Prevention. 9.1 Aspirin and Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). This book focuses on the functional significance of targeting apoptosis for the treatment of prostate cancer. New concepts on the challenges relating to the development of resistance by androgen-independent tumors are introduced, in terms of the contribution of anoikis and cross-talk of androgens with key growth factor signaling pathways. This volume also provides insightful discussion on the exploitation of the apoptotic and angiogenic synergism towards complete eradication of prostate tumors. Last but not least, it includes reflections on the drug development challenge based on the analysis. Print version record. Prostate Cancer Treatment. Apoptosis. http://id.loc.gov/authorities/subjects/sh91000743 Apoptosis https://id.nlm.nih.gov/mesh/D017209 Prostate Cancer Traitement. Apoptose. HEALTH & FITNESS Diseases Cancer. bisacsh MEDICAL Oncology. bisacsh Apoptosis fast Prostate Cancer Treatment fast has work: Molecular exploitation of apoptosis pathways in prostate cancer (Text) https://id.oclc.org/worldcat/entity/E39PCFPBpRgGyTjmhkxtHdxVqP https://id.oclc.org/worldcat/ontology/hasWork Print version: Kyprianou, Natasha. Molecular Exploitation of Apoptosis Pathways in Prostate Cancer. Singapore : World Scientific, ©2012 9781848164499 Molecular medicine and medicinal chemistry. http://id.loc.gov/authorities/names/n2011180846 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=457203 Volltext |
| spellingShingle | Kyprianou, Natasha Molecular Exploitation of Apoptosis Pathways in Prostate Cancer. Molecular medicine and medicinal chemistry. Preface; Contents; Chapter 1 Introduction: Prostate Cancer; Chapter 2 The Prostate Gland Dynamics; Chapter 3 Apoptosis Pathways Signaling Execution of Cancer Cells; 3.1 Cell Choices of Life and Death; 3.1.1 "Classic" apoptosis; 3.1.2 Anoikis; 3.2 Caspases: The Apoptosis Executioners in a Therapeutic Setting; 3.3 The Mitochondrion: A Convenient Cell-Killing Platform; 3.4 Cell Surface Death Receptors and the FAS Ligand; 3.5 Meet the BCL-2 Family: Governors of Cell Survival and Death; 3.6 The Transcriptional Controllers; 3.7 The p53 Tumor Suppressor. 3.8 PTEN/PI3K/AKT: The Downstream Intracellular Players3.9 The Antagonists of Death: Inhibitors of Apoptosis Proteins (IAPs); 3.10 Apoptosis Signaling in the Endoplasmic Reticulum: A Death Platform for Stress; 3.11 The Tumor Microenvironment: Extracellular Forces Control Intracellular Death Outcomes; 3.11.1 Role of hypoxia; 3.11.2 The key growth factors; 3.11.3 Inflammation; Chapter 4 Androgen Receptor-Mediated Apoptosis: Significance in Development of Castration-Resistant Prostate Cancer; 4.1 The Androgen Receptor (AR); 4.2 Androgen Ablation: The Glory and the Failures. 4.3 AR Status in Castration-Resistant Prostate Cancer4.4 AR Interactions with Growth Factor Signaling Leads to Apoptosis; 4.4.1 AR connects with EGF; 4.4.2 AR and IGF interactions; 4.4.3 AR and TGF-ß: partners in life and death (of the cell); 4.4.4 AR and FGF interactions; 4.4.5 AR and VEGF: Vascular exchanges for the "road"; 4.4.6 AR and growth factor interplay in the stroma; Chapter 5 Anoikis in Prostate Cancer Metastasis; 5.1 Anoikis Interrupted: Survival of the Homeless (Cells); 5.2 The Integrin Connection; 5.3 Impairing the Route to Angiogenesis; 5.3.1 Doxazosin; 5.3.2 Suramin. 5.3.3 Thalidomide5.3.4 Bevacizumab; 5.3.5 SU5416; 5.4 Anoikis and the Tumor Microenvironment: No "Resting" in the Stroma; 5.5 Signaling the "Homeless" State: Intracellular Anoikis Effectors; 5.6 Significance of Apoptosis in Cytoskeleton and Microtubule Targeting; 5.7 Autophagy: The Cellular Benefits of Starving to Death; Chapter 6 Epithelial-Mesenchymal Transition (EMT) in Prostate Cancer Metastasis; Chapter 7 Novel Molecular Therapeutics for Targeting Castration-Resistant Prostate Cancer; 7.1 Therapeutic Targeting of TGF-ß Signaling. 7.2 Exploitation of Quinazolines: Lifting Anoikis Resistance to Impair Metastasis7.3 Receptor Tyrosine Kinase Targeting; 7.4 Histone Deacetylase Inhibitors (HDACs): Therapeutic Inhibitors; 7.5 Selective Death Action by Cancer-Specific PAR-4 in Prostate Tumors; 7.6 Death Synergy Between Proteosome and Death Receptor Leads to Tumor Regression; 7.7 The SERCA Pump as a Therapeutic Target; 7.8 Endothelin-Receptor Antagonists; 7.9 The Power of Sex Steroid Targeting; Chapter 8 Apoptotic-Based Molecular Markers of Therapeutic Response; Chapter 9 Role of Apoptosis in Prostate Cancer Prevention. Prostate Cancer Treatment. Apoptosis. http://id.loc.gov/authorities/subjects/sh91000743 Apoptosis https://id.nlm.nih.gov/mesh/D017209 Prostate Cancer Traitement. Apoptose. HEALTH & FITNESS Diseases Cancer. bisacsh MEDICAL Oncology. bisacsh Apoptosis fast Prostate Cancer Treatment fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh91000743 https://id.nlm.nih.gov/mesh/D017209 |
| title | Molecular Exploitation of Apoptosis Pathways in Prostate Cancer. |
| title_auth | Molecular Exploitation of Apoptosis Pathways in Prostate Cancer. |
| title_exact_search | Molecular Exploitation of Apoptosis Pathways in Prostate Cancer. |
| title_full | Molecular Exploitation of Apoptosis Pathways in Prostate Cancer. |
| title_fullStr | Molecular Exploitation of Apoptosis Pathways in Prostate Cancer. |
| title_full_unstemmed | Molecular Exploitation of Apoptosis Pathways in Prostate Cancer. |
| title_short | Molecular Exploitation of Apoptosis Pathways in Prostate Cancer. |
| title_sort | molecular exploitation of apoptosis pathways in prostate cancer |
| topic | Prostate Cancer Treatment. Apoptosis. http://id.loc.gov/authorities/subjects/sh91000743 Apoptosis https://id.nlm.nih.gov/mesh/D017209 Prostate Cancer Traitement. Apoptose. HEALTH & FITNESS Diseases Cancer. bisacsh MEDICAL Oncology. bisacsh Apoptosis fast Prostate Cancer Treatment fast |
| topic_facet | Prostate Cancer Treatment. Apoptosis. Apoptosis Prostate Cancer Traitement. Apoptose. HEALTH & FITNESS Diseases Cancer. MEDICAL Oncology. Prostate Cancer Treatment |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=457203 |
| work_keys_str_mv | AT kyprianounatasha molecularexploitationofapoptosispathwaysinprostatecancer |